Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481113 · ClinicalTrials.gov registry record · Phase 1
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04481113 is a Phase 1 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 8 participants.
The verdict
NCT04481113, a Phase 1 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive \[HR+\]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving abemaciclib and niraparib together before surgery may make the tumor smaller.
Interventions
- DRUG Abemaciclib
- DRUG Niraparib Tosylate Monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04481113
The ClinicalTrials.gov registry entry for NCT04481113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abemaciclib is the first listed.
NCT04481113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04481113 about?
NCT04481113 is a clinical study titled "Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer". This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive \[HR+\]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certa...
What is the current status of trial NCT04481113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-06-07. Estimated completion is 2025-06-20.
What interventions are being tested in trial NCT04481113?
The interventions under investigation include: Abemaciclib (DRUG), Niraparib Tosylate Monohydrate (DRUG).
Who is sponsoring clinical trial NCT04481113?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.